While the content and objectives of the product quality review differ somewhat by jurisdiction, they are generally used to verify the consistency and appropriateness of existing manufacturing processes and identify opportunities to improve product quality. They are an important quality assurance and process improvement tool. Product quality review is an accepted part of Good Manufacturing Practice (GMP) regulations in many parts of the world, and regular quality reviews are required by the US, the EU, and Canada. Through quality review, firms can detect and resolve quality issues early and maintain their reputation as a trusted source of high-quality medicines among regulators, trading partners, healthcare providers, and patients. It encourages pharmaceutical manufacturers to proactively assess product quality attributes across manufacturing and production processes and pushes firms in the pharmaceutical industry supply chain to carry out end-to-end product oversight, more effectively mitigate risks associated with the manufacturing of pharmaceutical products, and drive continual improvement throughout the product lifecycle. Livemint tops charts as the fastest growing news website in the world □ Click here to know more.The quality review process is an integral part of quality management in the pharmaceutical sector. The objective of the Motilal Oswal Small Cap Fund is to uphold a well-balanced portfolio, ensuring a minimum exposure of 65% to small-cap stocks. Over the last 15, 10, and 5 years, the Small Caps Index has generated lasting wealth for investors, compounding returns at rates of 19.32%, 20.34%, and 22.06%, respectively. This extensive stock universe presents ample opportunities for alpha creation, as fund managers can potentially pinpoint stocks trading at substantial discounts to their intrinsic valuation. The realm of small-cap stocks surpasses both large caps and midcaps, boasting 537 stocks with a market capitalization exceeding ₹2,000 crores. It compels us to go above and beyond, ensuring that our clients receive the best service and that we meticulously curate portfolios focusing on delivering superior returns." We recognise that this success comes with a heightened responsibility. Risk management plays a crucial role for investing in small caps and our rigorous framework will help us mitigate the volatility associated with small caps."Īkhil Chaturvedi, Chief Business Officer, Motilal Oswal AMC, added, “Our Small-cap NFO’s unprecedented and staggering collection is a testimony to our team's resilience, investors’ trust, and support of our IFA network and other platforms. Motilal Oswal Small Cap Fund seeks to apply this time-tested investing process to create a portfolio of predominantly Small-cap stocks. The subscription number is a testimony of investors’ confidence in Motilal Oswal’s investing process that seeks to build high-quality, high-growth investment portfolios. Speaking on the closure of NFO, Navin Agarwal, Executive MD & CEO, Motilal Oswal Asset Management Company, said, “We are thrilled with the remarkable success of our Small Cap Fund’s NFO collection, with a staggering collection of over ₹1350 crores. The earnings growth in the small-cap sector has seen a substantial compounded increase of 48% over the past two financial years. Lately, the Indian stock markets have witnessed a noteworthy upswing, particularly highlighted by the Small Cap 250 index, which has outperformed and taken the lead in impressive gains during 2023. The asset management company (AMC) has received support from approximately 5000 distribution partners, guiding investors for long-term wealth creation through investment in the fund. The fund has also succeeded in attracting SIP registrations, surpassing 15 crores across 24,000 investors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |